Abstract:Ductal Carcinoma in Situ (DCIS) is a malignant proliferation of the epithelial inside the breast duct, which does not invade the myoepithelial layer and, therefore, does not have the capacity to generate metastases. [1]. However, an upstaging after surgery is possible, since there may be a concomitant invasive lesion that was not diagnosed in the pathological examination from biopsy, being discovered only after the surgical procedure [1]. In the pre-screening mammography era, DCIS was diagnosed. more commonly in symptomatic women presenting with a palpable nodule, papillary flow, or through an incidental finding on a breast biopsy [2], accounting for 1-2% of cancer cases. [3]. After the advent of mammographic screening, the incidence has considerably increased among asymptomatic women with mammographic changes such as calcifications. [4]. Nowadays the diagnosis of DCIS corresponds to 20-25% of biopsies secondary to screening mammographic changes. [1]. As we do know that the chance of axillary metastasis is potentially null, old series where axillary dissection (AD) was performed ipsilareral to the index tumor, axillary involvement was observed in less than 1% of cases [9]. Objectives: Our objective in this study was to describe in a single breast cancer reference center the surgical treatment of patients diagnosed with DCIS (mastectomy or breast conservative surgery – BCS). Methods: A retrospective analysis was made using the Pérola Byington Hospital's database, from January 2011 to December 2019. During this period, 11,373 cases of breast cancer were treated int the institution and 812 (7.4%) were DCIS. Data was available and we could analyze 494 patients who underwent vacuum-guided biopsy guided by mammography or ultrasound and were diagnosed with DCIS and underwent surgical treatment at the Hospital. We grouped the patients into 3 age groups: under 40, 40-49, and 50 and over. In all groups, we had patients who underwent SNB using the patent blue technique or AD and were evaluated using the H&E method. It is not part of the Institutional protocol to perform IHC in axillary lymph nodes. We had also evaluated the type of surgery (BCS or mastectomy) in each age group. Results: DCIS was diagnosed through mammographic alterations in 62% of all cases and nuclear grade 2 was the most common, with 47%, followed by grade 3 and 1, 46% and 4%, respectively. In 2% of cases the data was missing. Comedoconecrosis was present in 78% of our specimens. BCS was the most frequently surgery performed (73% of cases), with the axillary approach being performed in 35% of these patients (32% for SNB and 3% for AD). While 27% of patients underwent radical surgery and in this group 92% were submitted to axillary approach (70% SNB and 22% AD). In the group of patients younger than 40 years, 74% of patients (17 out of 23 in total) underwent an axillary approach regardless of the type of surgery. When evaluating the predetermined age groups, we saw that most of our patients were 50 years or more (69%), followed by patients between 40-49 years (26%) and 5% in patients under 40 years. In 3% of cases (16 in 494) we reclassified the lesion as invasive carcinoma. None of them had a lymph node involved by malignant cells after surgery and that's include the cases reclassified as invasive carcinoma. Conclusion: The results obtained in this analysis showing no axillary involvement will make us rethink the indications for the concomitant surgical approach of the breast and the axilla in cases with a diagnosis of DCIS as a way to reduce the axillary surgical overtreatment. It was not our goal to compare the costs and complications of each method of diagnosis and the prognostic factors after the treatment of DCIS. Citation Format: Andressa Amorim, Andre Mattar, Marcellus Ramos, Reginaldo Coelho Lopes, Luciana Damous, Luiz Henrique Gebrim. Ductal carcinoma in situ: An excess regard of the axilla? [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr PO5-03-02.

Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS

Treatment and Survival Outcomes of Lobular Carcinoma in Situ of the Breast: a SEER Population Based Study

Upgrade rates of variant lobular carcinoma in-situ (LCIS) compared to classic LCIS diagnosed in core needle biopsies: A ten-year single institution retrospective study

Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants

Survival Following Breast-Conserving Therapy is Equal to That Following Mastectomy in Young Women with Early-Stage Invasive Lobular Carcinoma.

Abstract P3-05-27: The impact of co-existing ductal carcinoma in situ in invasive early hormone receptor positive breast cancer on the genomic and clinical risk of recurrence

Risk Factors for Lymph Node Metastasis and the Impact of Adjuvant Chemotherapy on Ductal Carcinoma in Situ with Microinvasion: a Population-Based Study.

Pathologic Characteristics of Breast Cancer that Predict for Local Recurrence After Lumpectomy Alone

Abstract PS01-08: Management of ipsilateral breast tumor recurrence following breast conservation surgery for ductal carcinoma in situ – a data-free zone

Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)

Locoregional recurrence and survival of breast−conserving surgery compared to mastectomy following neoadjuvant chemotherapy in operable breast cancer

Outcomes from low-risk ductal carcinoma in situ: a systematic review and meta-analysis

Surveillance Strategies After Primary Treatment for Patients with Invasive Lobular Carcinoma of the Breast: Method of Local Recurrence Detection After Breast-Conserving Surgery

The Oncologic Safety of Breast-Conserving Surgery for Breast Ductal Carcinoma in Situ

Ductal Carcinoma in Situ Has Comparable Prognosis but Different Risk Factors with Ductal Carcinoma in Situ with Micro Invasion

Abstract PO5-03-02: Ductal carcinoma in situ: An excess regard of the axilla?

[Safety of Breast-Conserving Treatment for Triple-Negative Breast Cancer].

Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment

Surgical outcomes and prognosis of HER2+ invasive breast cancer patients with a DCIS component treated with breast-conserving surgery after neoadjuvant systemic therapy

Oncological outcomes of post neo adjuvant chemotherapy breast conservation surgery in patients with locally advanced breast cancer

Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women